Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

On the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the adjusted mean difference between inebilizumab and ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score and 87% of the patients demonstrated a ≥ 5-point reduction in ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...